CGEM — Cullinan Therapeutics Share News
0.000.00%
Last trade - 00:00- $960.17m
- $625.63m
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
U.S. STOCKS ON THE MOVE-Five Below, Salesforce, IBM, Akamai Technologies
Cullinan climbs as lung cancer drug meets late-stage trial goal
Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint In Planned Interim Analysis Of Phase 3 Rezilient3 Trial
Cullinan Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cullinan Therapeutics Q2 net loss narrows
Brief: Cullinan Therapeutics Q2 Operating Income USD -57.254 Million Vs. IBES Estimate USD -57.1 Million
U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner
U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner
Cullinan rises as early-stage data show remission in autoimmune disease drugs
Brief: Cullinan Therapeutics Inc Cln-978 Shows Favorable Safety Profile With Single Target Doses Up To 30 Μg As Well As Initial Multi-Dose Regimen
Cullinan Therapeutics Q1 net loss widens
Brief: Cullinan Therapeutics Q1 Operating Expenses USD 53.697 Million
Brief: Cullinan Therapeutics Inc Files For Mixed Shelf Offering
Cullinan Therapeutics Q4 net loss widens
Brief: Cullinan Therapeutics Q4 Operating Expenses USD 55.259 Million
U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday
Brief: Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy